Actavis (ACT) Tops Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Actavis (ACT) Price Target Raised to $254 at UBS
August 6, 2014 11:21 AM EDTUBS maintained a Buy rating on Actavis (NYSE: ACT) and raised its price target to $254.00 (from $237.00). The change follows Q2 results.
Analyst Marc Goodman said, "(1) Mgt has aspiration of $20.00 EPS for 2017, which will depend on both new branded and generics product... More
